retatrutide triple agonist glp-1 gip glucagon phase 3 2025 What Makes Powder a Breakthrough Triple-Agonist API? Triple G Agonists – Retatrutide.

The approval gives Novo Nordisk temporary market exclusivity in oral obesity therapies, putting it ahead of Eli Lilly, whose orforglipron small-molecule medicine isnt anticipated to be available until 2026

[DOI] [PMC free article] [PubMed] [Google Scholar] 90.Huang J., Zhang Z., Liu B., Gao Y., Nie J., Wen S., Lai X., Liang H

Aspiration and regurgitation risk With as many articles agreeing on the risks of delayed gastric emptying and increased residual gastric contents among GLP-1 RA users, a similar proportion of articles disagreed on the additional risk of aspiration or regurgitation events

Whats also important is that this weight loss was sustained for up to 48 weeks